Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 16/20 | 0.65 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936309 | 0.97 | GLP1R (0.65) | GLP1R | |
| SCHEMBL31688323 | 0.89 | GLP1R (0.66) | GLP1R | |
| SCHEMBL20816299 | 0.89 | GLP1R (0.80) | GLP1R | |
| SCHEMBL30587681 | 0.89 | GLP1R (0.72) | GLP1R | |
| SCHEMBL30592733 | 0.89 | GLP1R (0.55) | GLP1RIL23R | |
| SCHEMBL30216755 | 0.88 | GLP1R (0.72) | GLP1RIL23R | |
| SCHEMBL9237145 | 0.88 | IL23R (0.63) | GLP1RIL23R | |
| SCHEMBL9237225 | 0.88 | IL23R (0.63) | GLP1RIL23R | |
| SCHEMBL31072729 | 0.88 | GLP1R (0.81) | GLP1R | |
| SCHEMBL30451312 | 0.88 | C5AR1 (0.70) | GLP1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3603658-B1 | PEPTIDE FOR USE IN THE TREATMENT OF HEART FAILURE RESULTING FROM HYPERTROPHIC CARDIOMYOPATHY | UNIV CORNELL (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4285994-A2 | METHODS FOR THE PREVENTION OR TREATMENT OF NO-REFLOW FOLLOWING ISCHEMIA/REPERFUSION INJURY | Stealth BioTherapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230285499-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230149501-A1 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3513800-B1 | AROMATIC-CATIONIC PEPTIDE FOR USE IN THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME | UNIV CORNELL (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11366104-B2 | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-4005582-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285499-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | TNNI3, FABP3, TNNC1 | GLP1R 142/4885IL23R 4061/4885 |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | GLP1R 34/4885IL23R 3422/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | GLP1R 2360/4885IL23R 4208/4885 |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | TNNI3, FABP3, TNNC1 | GLP1R 142/4885IL23R 4061/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | GLP1R 1187/4885IL23R 2694/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | GLP1R 2360/4885IL23R 4208/4885 |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | GLP1R 1920/4885IL23R 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.